** Shares of Ascentage Pharma Group International 6855.HK jump 12.3% to HK$43.45, a peak since Jan. 6
** Stock on track for biggest one-day pct rise since Aug. 26, 2024
** Ascentage, backed by Japan's biggest drugmaker Takeda Pharmaceutical 4502.T, said on Tuesday it was targeting a valuation of $1.75 bln in its initial public offering, becoming the first sizeable Chinese firm to pursue a listing in the U.S. this year
** Ascentage, which is focused on developing and commercializing therapies that target malignancies, is looking to raise $149 mln by offering about 7.3 mln American depositary shares at $20.34 each
** Shares of Takeda Pharmaceutical 4502.T up 0.2%
** Hong Kong's healthcare index .HSCIH slips 0.5% and Hang Seng Index .HSI falls 1.4%
** Ascentage stock soared 66.5% last year
(Reporting by Donny Kwok)
((donny.kwok@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.